References
- 1
Pitocco D, Ruotolo V, Caputo S, Mancini L, Collina MC, Manto A, Caradonna P, Ghirlanda G.
Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized
controlled trial.
Diabetes Care.
2005;
28
1214-1215
- 2
Haylor J, Singh I.
Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor
I.
Kidney Int.
1991;
39
333-335
- 3
Kapitola J, Zak J, Jutova V.
Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I
levels in the rat.
Physiol Res.
2000;
49
((Suppl 1))
S101-S106
- 4
Cortet B.
Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy
and safety of the second generation bisphosphonate pamidronate.
Clin Rheumatol.
1997;
16
51-56
- 5
Rubin J.
IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB
ligand in vitro and OPG in vivo.
J Clin Endocrinol Metab.
2002;
87
4273-4279
- 6
Tracey KJ.
The inflammatory reflex.
Nature.
2002;
120
853-859
- 7
Ueland T.
GH/IGF-I and bone resorption in vivo and in vitro.
Eur J Endocrinol.
2005;
152
327-323
- 8
Saidenberg-Kermanac’h N, Bessis NC.
Osteoprotegerin and inflammation.
Eur Cytokine Netw.
2002;
13
144-153
- 9
Lam J, Abu-Amer Y.
Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory
osteolysis.
Ann Rheum Dis.
2002;
61
((Suppl 2))
ii82-ii83
- 10
Kostenuik PJ.
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
Curr Opin Pharmacol.
2005;
5
618-625
Correspondence
D. Pitocco
Internal Medicine Institute
Catholic University
L. go A. Gemelli 8
00168 Rome
Italy
Telefon: +39/06/30 15 40 71
Fax: +39/06/30 50 05 2
eMail: dario.pitocco@rm.unicatt.it
